[
    [
        {
            "time": "2023-10-01",
            "original_text": "Novartis Gets EC Approval for Enerzair Breezhaler for Asthma",
            "features": {
                "keywords": [
                    "Novartis",
                    "EC Approval",
                    "Enerzair Breezhaler",
                    "Asthma"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Novartis",
                    "Equinix",
                    "Newmont",
                    "Enterprise Products Partners",
                    "Franco-Nevada"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "real estate",
                    "mining",
                    "energy"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold",
            "features": {
                "keywords": [
                    "Novavax",
                    "COVID-19 Vaccine",
                    "Amgen",
                    "Avastin Biosimilar",
                    "Cellectis",
                    "Clinical Hold"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Yates Class Action Law Encourages Long Term Stockholders of Novartis AG (NYSE: NVS) to Contact The Firm",
            "features": {
                "keywords": [
                    "Class Action",
                    "Novartis AG",
                    "Stockholders"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "legal",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        }
    ]
]